Our findings uncover the clinical application of SOX2 expression as an independent predictor of laryngeal cancer risk in patients with laryngeal precancerous lesions, showing superior predictive value to the current World Health Organization (WHO) histological classification. Here, SOX2 is linked to laryngeal carcinoma.